Istodax

CTAGE1 protein, human
Treatment
11 Active Studies for Istodax

What is Istodax

RomidepsinThe Generic name of this drug
Treatment SummaryRomidepsin is a medication used to treat cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) that have not responded to other treatments. It was approved by the FDA in 2009 and works by blocking certain enzymes that cause cancer cells to spread. While it has been shown to improve response rates, its effects on overall survival have yet to be proven.
Istodaxis the brand name
image of different drug pills on a surface
Istodax Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Istodax
Romidepsin
2009
8

Effectiveness

How Istodax works in the bodyRomidepsin is a drug that targets cancer cells by inhibiting a specific enzyme, called HDAC. In some cancers, the levels of HDAC are higher than normal, which can turn off important regulatory genes and cause the growth of tumors. Romidepsin works by blocking HDAC, restoring normal gene expression and causing the cancer cells to stop growing and die.

When to interrupt dosage

The prescribed dosage of Istodax is contingent upon the diagnosed state. The quantity likewise fluctuates, in line with the method of administration cited in the table beneath.
Condition
Dosage
Administration
CTAGE1 protein, human
, 10.0 mg, 10.0 mg/mL, 5.0 mg/mL
, Kit, Intravenous, Kit; Powder, for solution, Kit; Powder, for solution - Intravenous, Kit - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Warnings

There are 20 known major drug interactions with Istodax.
Common Istodax Drug Interactions
Drug Name
Risk Level
Description
Artemether
Major
The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Artemether.
Asenapine
Major
The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Asenapine.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Romidepsin.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Romidepsin.
Clonidine
Major
The metabolism of Clonidine can be decreased when combined with Romidepsin.
Istodax Toxicity & Overdose RiskRomidepsin is not recommended during pregnancy due to an unknown risk factor. If a nursing mother takes this drug, she should consider stopping breastfeeding or the drug, depending on how important the treatment is for her. Many patients who take romidepsin also experience nausea, vomiting, or loss of appetite.
image of a doctor in a lab doing drug, clinical research

Istodax Novel Uses: Which Conditions Have a Clinical Trial Featuring Istodax?

No current clinical trials are investigating the utility of Istodax in treating Lymphoma, Cutaneous T-Cell Disorders.
Condition
Clinical Trials
Trial Phases
CTAGE1 protein, human
10 Actively Recruiting
Phase 1, Not Applicable, Phase 2, Early Phase 1, Phase 3

Istodax Reviews: What are patients saying about Istodax?

3Patient Review
5/16/2011
Istodax for Cutaneous T-Cell Lymphoma
The drug infusion itself only takes 4 and 1/2 hours, but there's also the approximately 1/2 hour infusion of an anti-nausea agent first. Then there is the 1 to 2 hour wait for the blood draw results. Somehow this neeeds to be streamlined.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about istodax

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is istodax chemo?

"It is classified as a "topoisomerase II inhibitor." Istodax is a chemotherapy drug that inhibits topoisomerase II."

Answered by AI

What is istodax used for?

"ISTODAX is a prescription medicine used to treat people with a type of cancer called cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL) after at least one other type of medicine by mouth or injection has been tried. It is not known if ISTODAX is effective in children under the age of 18."

Answered by AI

Why was romidepsin taken off the market?

"Bristol Myers Squibb announced today that it is withdrawing romidepsin (Istodax) as a treatment option for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) in the United States. This decision is based on the lack of beneficial effects of romidepsin identified in the confirmatory phase 3 Ro-CHOP trial (NCT01796002)."

Answered by AI

How is istodax administered?

"Romidepsin is indicated as a treatment for cutaneous T-cell lymphoma for patients who have received at least one prior systemic therapy. The recommended dose is 14 mg/m2 administered intravenously over a 4-hour period on days 1, 8 and 15 of a 28-day cycle."

Answered by AI

Clinical Trials for Istodax

Have you considered Istodax clinical trials? We made a collection of clinical trials featuring Istodax, we think they might fit your search criteria.
Have you considered Istodax clinical trials? We made a collection of clinical trials featuring Istodax, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security